Pulse Biosciences (NASDAQ:PLSE) posted its earnings results on Thursday. The company reported ($0.57) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.61) by $0.04, Fidelity Earnings reports.
PLSE stock traded up $0.08 during midday trading on Friday, hitting $14.39. 63,300 shares of the company’s stock were exchanged, compared to its average volume of 56,101. The stock’s fifty day moving average price is $14.95 and its 200-day moving average price is $13.25. The company has a market cap of $306.54 million, a PE ratio of -6.54 and a beta of 1.84. The company has a debt-to-equity ratio of 0.07, a quick ratio of 12.92 and a current ratio of 12.92. Pulse Biosciences has a one year low of $9.52 and a one year high of $19.77.
Several research firms have weighed in on PLSE. BidaskClub lowered Pulse Biosciences from a “hold” rating to a “sell” rating in a report on Thursday, October 31st. ValuEngine upgraded Pulse Biosciences from a “sell” rating to a “hold” rating in a report on Wednesday, October 30th.
Pulse Biosciences, Inc operates as a clinical stage medical therapy company. It engages in the research and development, and commercialization of CellFX system that provides a precise and non-thermal cellular treatment technology delivering nanosecond duration energy pulses that impact cells in treated tissue while sparing surrounding non-cellular tissue primarily for dermatology applications.
Recommended Story: Buy Rating
Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.